CRC: Clinical Trials

3 trials for CRC, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated. 3 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 13Terminated 3
Phase 22Terminated 2

Follow CRC: new trials by email Literature Review of CRC trials Research Report on CRC

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
BMF-219 - Non Small Cell Lung Cancer, Pancreatic Cancer
Phase 1TerminatedBiomea Fusion Inc.132023-01-122025-02-07
Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours
OMO-103 - Advanced Solid Tumors, Pancreatic Cancer
Phase 1 / Phase 2TerminatedPeptomyc S.L.222021-04-282024-04-25
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
CB-839, Talazoparib - Solid Tumor, Clear Cell Renal Cell Carcinoma
Phase 1 / Phase 2TerminatedCalithera Biosciences, Inc332019-05-202022-02-17

Narrower conditions

Colorectal Neoplasms (2)  ·  Pancreatic Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Carcinoma, Renal Cell (1)  ·  Neoplasm Metastasis (1)  ·  Neoplasms (1)  ·  Recurrence (1)  ·  Triple Negative Breast Neoplasms (1)

Broader conditions

Digestive System Diseases (3)  ·  Digestive System Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Colonic Diseases (2)  ·  Endocrine Gland Neoplasms (2)  ·  Endocrine System Diseases (2)  ·  Gastrointestinal Diseases (2)  ·  Gastrointestinal Neoplasms (2)  ·  Intestinal Diseases (2)  ·  Intestinal Neoplasms (2)  ·  Neoplasms (2)  ·  Pancreatic Diseases (2)  ·  Rectal Diseases (2)  ·  Adenocarcinoma (1)  ·  Breast Diseases (1)

Interventions

CB-839 (1)  ·  talazoparib (1)

Sponsors

Biomea Fusion Inc. (1)  ·  Calithera Biosciences, Inc (1)  ·  Peptomyc S.L. (1)

Countries

United States (2)  ·  South Korea (1)  ·  Spain (1)

Top investigators

Elena Garralda, MD, PhD (1)  ·  Sam Whiting, MD, PhD (1)  ·  Steve Morris, MD (1)

Results publications

PMID 38321218, PMID 40148035